We studied the pharmacokinetics and QT interval pharmacodynamics of a single 10 mg dose of oral haloperidol in a randomized, double-blind, placebo-controlled, crossover trial of healthy poor (PMs) and extensive (EMs) metabolizers of CYP2D6. There was a statistically significant greater mean QT c on haloperidol (421.6720.1 ms) than on placebo (408.4718.5 ms, P ¼ 0.0053) occurring 10 h post haloperidol/placebo administration. Men and women had similar ranges of QT c changes from placebo. Despite a statistically significant greater mean elimination half-life (19.173.6 vs 12.974.0 h, P ¼ 0.04) and lower mean apparent oral clearance (12.874.1 vs 27.0711.3 ml/min/kg, P ¼ 0.02) of haloperidol in CYP2D6 PMs than in EMs, this exposure change did not translate into marked QT c changes from baseline that could be considered clinically important. Although the magnitude of the mean QT c prolongation on haloperidol relative to placebo is relatively small, it may assume significance in the presence of other risk factors for QT prolongation. The Pharmacogenomics Journal (2003) 3, 105-113. doi:10.1038/sj.tpj.6500160
INTRODUCTION
Schizophrenia is a common psychiatric disease with a lifetime prevalence of nearly 1% of the general population 1 that is associated with an increased risk of premature death. A recent meta-analysis revealed that schizophrenic patients are 1.5 times more likely of dying from all causes compared to an age-and gendermatched cohort of the general population. 2 While it is not known how much of this excess risk can be attributed to antipsychotic-induced cardiotoxicity, it is clear that many antipsychotics are arrhythmogenic. 3 Among the antipsychotic drugs, haloperidol remains one of the most widely used worldwide. Haloperidol-induced ventricular arrhythmias of the torsades de pointes (TdP) type have been reported with a range of doses starting as low as 4 mg 4 administered over a 24 h period and as high as 825 mg 5 over a 24-h period. Cardiac side effects at high doses likely involve excessive exposure to haloperidol. However, the extent to which low doses of haloperidol contribute to QT interval prolongation in the absence of risk factors 6 such as age, concomitant medications, electrolyte imbalances, ischemic heart disease, or congenitally prolonged QT intervals is less well characterized. Prolongation of the QT interval is a biomarker for the malignant ventricular arrhythmia of TdP.
In vitro cardiac electrophysiology studies that we have conducted demonstrate that supratherapeutic concentrations of haloperidol prolong the heart rate corrected QT interval (QT c ) by approximately 26% in an isolated perfused feline heart model. 7 The mechanism of haloperidol-mediated QT prolongation involves blockade of the rapidly acting delayed rectifier potassium channel (I Kr ). Haloperidol, has been shown to block this channel expressed in Xenopus oocytes in a concentration-dependent manner with an IC 50 of 1 mM. 8 Despite the clear ability of haloperidol to bring about relevant changes in ion channel activity in vitro and a number of incriminating case reports of cardiotoxicity, 9 the ability of therapeutic doses of haloperidol to prolong the QT c interval in healthy subjects without the presence of interacting drugs is not known.
Cytosol reductase is the enzyme that converts haloperidol to reduced haloperidol, an active metabolite. 10, 11 Reduced haloperidol can be oxidized back to haloperidol by cytochrome P450 isoforms CYP3A4 and CYP2D6. 12, 13 Multiple clinical studies have shown that CYP2D6 genotype influences haloperidol and reduced haloperidol pharmacokinetics. [14] [15] [16] However, it is not known to what extent CYP2D6 genotype influences haloperidol-induced QT interval pharmacodynamics.
The primary objective of the present study was to determine the potential for a commonly used clinical dose of haloperidol to alter the QT c interval in healthy subjects in a prospective, randomized controlled trial. The secondary objectives of the study were to determine the influence of CYP2D6 genotype on haloperidol disposition and QT interval pharmacodynamics.
RESULTS
A total of 16 healthy subjects participated in the study. Subject demographics are presented in Table 1 . The body mass index (BMI) ranged from 21.4 to 31.6 kg/m 2 in all subjects with males (25.873.6 kg/m 2 ) having a greater BMI compared to females (22.471.4 kg/m 2 ) (P ¼ 0.036). In all, eight of the volunteers were CYP2D6 *1 homozygotes, two were *4 heterozygotes, two were *10 heterozygotes, one was a *17 homozygote, and three were *4 homozygotes. One subject who started the study dropped out because of severe anxiety and restlessness 4 h postdosing. At 10 h postdosing, the mean heart rate was 62.376.5 beats per minute (bpm) and 56.378.1 bpm on haloperidol and placebo, respectively (P ¼ 0.003 pre-Bonferonni and P ¼ 0.039 post-Bonferonni). The heart rate was not statistically significantly different between the two groups at any other time point during the study.
Subject-specific QT Correction Model
The slopes of the QT c vs RR linear regression lines derived from Bazett's, Fredericia's, and the subject-specific heart rate correction formulae were compared using placebo (off-drug) response data. The goal of heart rate correction of the QT interval was to obtain a QT c vs RR linear regression line with a slope as close to zero as possible. As shown in Figure 1 , the mean absolute slope7SD of the QT c interval (ms) vs RR interval (ms) regression line for placebo period data using the subject-specific correction (0.02270.014) was significantly lower than the mean absolute slopes using Fredericia's correction (0.04370.028, P ¼ 0.04) or Bazett's correction (0.1070.049, P o0.0001). Since the subjectspecific correction generated QT c vs RR linear regression lines with the smallest absolute slopes, we chose to present study results using this correction method. Using linear mixed modeling for QT correction, the mean a7standard error of the mean (SEM) for our study sample was 0.2970.02 (range 0.23-0.38). Alpha (a) was defined as the slope of the log transformed QT vs RR relation using the subject-specific heart correction method. The terms corresponding to a in both the Bazett and Fredericia heart rate correction formulae were constant at 1/2 and 1/3, respectively.
Pharmacokinetics
The mean7SD pharmacokinetic parameters of haloperidol for the 16 subjects are shown in Table 2 . As shown in Table 3 , there was no statistically significant difference between females and males with respect to clearance (25.2712.3 vs 23.3711.8 ml/min/kg, P ¼ 0.72), half-life (15.172.4 vs 13.175.9 h, P ¼ 0.28), and AUC (132.1766.8 vs 107.17 47.6 ng h/ml, P ¼ 0.50) for the 10 mg dose. Reduced haloperidol, an active metabolite of haloperidol, was below detectable limits in the majority of subjects and therefore a pharmacokinetic profile of this metabolite is not reported. All but one of the subjects in whom this metabolite was detected Values are reported as the mean7SD of subjects completing the study. were poor metabolizers (PMs). In the three PMs receiving the 10 mg dose, the mean C max was 1.23 ng/ml occurring between 24 and 48 h after haloperidol administration. In the single extensive metabolizer (EM) in whom it was detected, the C max was 0.696 ng/ml occurring at 8 h postdose. The effects of CYP2D6 genotype on haloperidol pharmacokinetics are shown in Figure 2 . The mean terminal elimination half-life of haloperidol was statistically significantly higher in PMs (19.174 .0 h) compared to EMs (12. 974.0 h, P ¼ 0.04) (Figure 2a) . The mean apparent oral clearance of haloperidol was significantly lower in PMs (12.874.1 ml/min/kg) compared to EMs (27.0711.3 ml/ min/kg) (P ¼ 0.02) (Figure 2b ). The maximal plasma concentrations of haloperidol achieved were 6.170.3 and 7.973.9 in PMs and EMS, respectively and were not statistically significantly different.
QT Interval Pharmacodynamics
As expected, the time averaged QT c 's7SD off drug (placebo only) were 416.8717.9 and 408.9716.6 ms in females and males, respectively (P ¼ 0.001), which is consistent with findings in the medical literature that suggest females in general have longer QT intervals than males in the absence of drug therapy. Figure 3a shows the mean QT c 's7SD in the treatment and placebo groups at each time point during the study. At the 10 h time point, the mean QT c 's were 421.6720.1 and 408.4718.5 ms on haloperidol and placebo, respectively (P ¼ 0.00041 pre-Bonferonni, P ¼ 0.0053 post-Bonferonni). At the 4-and 6-h time points, there were trends towards a greater mean QT c on treatment than placebo but after Bonferonni's correction the trend was nullified. Figure 3b shows both the haloperidol-induced mean QT c changes from placebo and the mean haloperidol plasma concentrations as a function of time post dosing. The QT c change is defined as the QT c on treatment at a given time point less the QT c on placebo at the corresponding time point. Males and females had significant overlap in their maximal QT c changes from placebo as shown in Figure 4a . There was also significant overlap in QT c changes from placebo at T max (the time point where maximal haloperidol plasma concentrations were achieved) ( Figure 4b ). Similarly among PMs and EMs of CYP2D6, there was significant overlap between the QT c changes from placebo as shown in Figure 4c and 4d.
There was significant overlap in the maximal QT c change from baseline (time 0 time point) in the treatment and placebo groups as shown in Figure 5a . Similarly, significant overlap in the QT c change from baseline occurred at the time point when maximal haloperidol plasma concentrations were achieved as shown in Figure 5b .
The maximal change in QT c relative to baseline observed in a single individual at any time post haloperidol administration was 8.8%. Similarly, the maximal change in QT c relative to baseline observed in any subject receiving placebo was 7.2%, illustrating potential for significant variability of this measurement in the absence of any treatment.
There was poor correlation between plasma haloperidol concentrations and QT c change from placebo during the first 10 h of the study (R 2 ¼ 0.007, P40.30) (figure not shown).
Adverse Effects
No subject was discontinued from the study because of haloperidol-induced arrhythmia or other cardiac adverse event. One volunteer who started the study, dropped out because of severe anxiety and restlessness starting 4 h after receiving haloperidol. The most common side effects seen with haloperidol were anxiety and restlessness of variable intensity that occurred in 12 of 16 subjects (75%) completing the study. Other less common side effects that occurred at a frequency of between 10 and 40% were difficulty concentrating, feeling tired or sleepy, decreased appetite, dry mouth, blurred vision, dystonia, and vivid dreams. Three subjects experienced dystonia between 24 and 36 h after dosing and were successfully treated with diphenylhydramine 25 mg orally.
Subjects experiencing dystonia requiring diphenylhydramine did not differ significantly in haloperidol pharmacokinetic parameters compared with those not experiencing these side effects. Subjects experiencing dystonia showed a mean clearance of 15.374.1 ml/min/kg, while those not experiencing this side effect showed a mean clearance of 26.02712.4 ml/min/kg (P ¼ 0.071). The mean C max of haloperidol in subjects experiencing dystonia was 9.474.2 ng/ml, while the C max in subjects not experiencing dystonia was 7.173.4 ng/ml (P ¼ 0.35). Similarly, there was no statistically significant difference in the mean plasma concentration vs time area under the curve between the two groups (158794 vs 111747 ng h/ml, P ¼ 0.35). The CYP2D6 genotypes for the three subjects who experienced dystonia were *4 heterozygote, *10 heterozygote, and *4 homozygote.
DISCUSSION
We conducted a study of the effects of routinely used, low doses of oral haloperidol on the electrocardiographic QT interval pharmacodynamics in healthy volunteers not on concomitant medications. To improve the mechanistic understanding of our data, we determined the pharmacokinetics of haloperidol in each subject and the effect of CYP2D6 genotype on pharmacokinetics and QT interval pharmacodynamics. We chose to study a healthy population because of the potential for multiple, confounding, drug and disease interactions in a patient population and because of the specific potential for ion channel variants to occur in the hearts of patients with schizophrenia. Potassium channel variants have been reported in the brains of schizophrenics. 17 Single doses rather than multiple doses were used because of the intolerability of the latter study design in normal, healthy volunteers.
Our data showed a statistically significant mean QT c prolongation of approximately 13 ms relative to placebo occurring 10 h post oral haloperidol administration. This difference could not solely be the result of intraobserver variability in QT interval assessment because there was only a mean 1.3 ms difference at time 0 (baseline) in both the placebo and haloperidol treatment periods. This 1.3-ms difference likely reflected the sum of both intra-observer variability and intraindividual variability in the QT/QT c and accounted for about 10% of the change seen at the 10-h time point.
Our results differ from other studies in the literature that suggest haloperidol does not cause statistically significant QT c prolongation when used in relatively low doses. Fulop et al 18 reported a nonsignificant QT c prolongation of o4 ms at the end of 6 weeks of treatment with oral haloperidol (doses up to 10 mg/day) in patients with Tourette's syndrome. 19 The mean dose used in Fulop's study was approximately 5 mg a day. There are major differences in the two study designs. The obvious difference was that our study was a single-dose study whereas Fulop's was a multidose study. In our study, all subjects receiving haloperidol also served as their own controls, whereas in Fulop's study only a limited number of subjects had both a placebo and treatment period. Additionally, we had a comprehensive placebo period during which ECG sampling was intensively performed, therefore allowing us to monitor the natural fluctuations of QT c in the absence of treatment. Intense placebo period ECG sampling was not performed in Fulop's study. Also in our study, we acquired ECGs at multiple prespecified time points post haloperidol administration allowing us to detect QT c changes that were delayed from peak plasma concentrations. In Fulop's study, acquiring only a single ECG at the end of the study may have caused a peak QT effect that was significantly delayed from the peak plasma concentration to be missed. Additionally using a range of doses up to 10 mg may have diluted the power to detect an effect at any specific dose (eg 10 mg). Another possibility of a lack of effect in Fulop's chronic dose study could be tolerance to I Kr blockade. It is unclear if this phenomenon occurs with haloperidol or other drugs. In general, we believe our study had greater sensitivity to detect an effect of haloperidol on the QT c interval than did Fulop's study.
We found a small but statistically significant effect of CYP2D6 genotype on haloperidol pharmacokinetics in that the terminal elimination half-life was greater and the apparent oral clearance was lower in PMs than in EMs. These findings were consistent with findings from other studies. 12, 14 However, the exposure differences attributed to CYP2D6 genotype were not sufficient to produce substantial haloperidol-induced QT c pharmacodynamic changes in PMs relative to EMs. A likely reason for this observation could be that CYP2D6 is not exclusively responsible for haloperidol disposition. It is known that several P450s and non-P450 enzymes are involved in this process, thus making it difficult for a deficiency in any particular metabolic pathway to markedly influence QT interval pharmacodynamics. Cytosolic ketoreductase is the enzyme responsible for conversion of haloperidol to reduced haloperidol. 10, 11 In vitro studies 
. 20 , 21 Yasui et al 22 showed that schizophrenic patients prescribed haloperidol 12-14 mg/day who were coadministered the CYP3A4 inhibitor, itraconazole, had significantly higher concentrations of the parent and active metabolite with an associated increase in the incidence of neurological side effects. A role for CYP1A2 has been suggested in haloperidol clearance but is controversial. 23, 24 The accumulated evidence suggests that multiple enzymes are involved in haloperidol metabolism, therefore diluting any specific effect of CYP2D6 genotype on QT c pharmacodynamics in our study.
Reduced haloperidol is formed from haloperidol by cytosolic ketoreductase and represents one of the major routes of haloperidol metabolism. In addition, there is evidence that reduced haloperidol is partially converted to haloperidol by CYP2D6. It is unlikely that reduced haloperidol contributes significantly to QT interval pharmacodynamics. Reduced haloperidol is a less potent inhibitor of the I Kr channel than its parent with an IC 50 ¼ 2.6 mM.
8 Also, it has been shown that when haloperidol is administered orally, plasma concentrations of the parent compound are at least two to three times higher than the metabolite. 12 Both the higher IC 50 and lower plasma concentrations achieved argue against a contribution of reduced haloperidol in prolonging the QT c interval. However, clinical studies involving administration of reduced haloperidol would be necessary to confirm this hypothesis.
Overall, our data clarify a number of important issues related to the arrhythmogenicity of haloperidol. First, the magnitude of the mean QT c change brought about by commonly used low doses of haloperidol is statistically significant but clinically small. While this magnitude of change will not manifest clinically in a majority of patients, there are individuals in whom the magnitudes of changes we detected may become important when other risk factors for QT prolongation or TdP are present (eg bradycardia, electrolyte abnormalities, genetic predisposition, drug interactions, etc.). Second, although the participation of CYP2D6 genotype in haloperidol disposition was confirmed, the pharmacokinetic changes observed were not sufficient to bring about clinically important pharmacodynamic consequences. Based on our findings, we believe that the routine acquisition of a screening electrocardiogram is warranted prior to use of low doses of oral haloperidol in otherwise healthy subjects not on concomitant medications. An electrocardiogram provides a relatively cheap, noninvasive, time-efficient, and simple to use screening tool that can be performed in an in-patient or outpatient setting that may help identify patients with risk factors such as genetic potassium channel variants and decreased repolarization reserve. Currently, there is no standard method for screening such individuals and the frequency with which these genetic variants occur in the general population is not known. Given the large medical, social, and economic burden of this disease, the benefits of haloperidol significantly outweigh the relatively small risk of drug-induced TDP when used in low doses in patients without risk factors for QT prolongation.
METHODS

Subjects
We studied 16 healthy, nonsmoking subjects using single 10 mg doses of oral haloperidol. All subjects were aged between 21 and 41 years. Subjects gave written informed consent prior to study participation. The study protocol was approved by the Institutional Review Board of Georgetown University Medical Center.
Subjects were included if there were no clinically significant abnormalities in their medical histories, physical examinations, hematologic tests, blood chemistries (including K + , Mg 2+ Ca 2+ ), or urine toxicologic tests. Female subjects were required to have a negative serum b-HCG 2 days prior to study initiation. Subjects were excluded if they had a screening electrocardiogram (ECG) with a baseline QT c greater than 440 ms by Bazett's correction or a history of any cardiac disease, including myocardial infraction, valvular heart disease, or cardiomyopathy. Subjects were also excluded if they were actively using any prescription or nonprescription drugs including oral contraceptives.
All study subjects were required to refrain from alcohol, grapefruit juice, and caffeine-containing beverages beginning 48 h prior to the study and throughout the study duration.
Study Design
This study was conducted in Georgetown University's General Clinical Research Center (GCRC). This protocol was a randomized, double-blind, placebo-controlled, single-dose crossover clinical trial. There were two study periods with each period lasting 4 days. During the first 24 h of each study period, subjects were required to stay in the GCRC overnight. There was a 3-day washout between the two study periods. Subjects were randomly assigned to receive either placebo or haloperidol (Geneva Pharmaceuticals Lot # 114748, Broomfield, CO, USA) at 8 am during the first study period and the alternative treatment at the identical time during the second study period. Subjects were observed to randomly receive placebo or haloperidol on an empty stomach after an overnight fast and were given breakfast approximately 1 h after dosing. Meals during the GCRC stay were standard with no citrus fruits or caffeine-containing beverages.
After a 24-h stay in the GCRC, subjects were discharged and returned every 12 h for the remainder of each study period. Blood samples for analysis of haloperidol concentrations were collected before and 2, 4, 6, 8, 10, 24, 36, 48, 60, 72, 84, and 96 h after administration of either placebo or haloperidol. ECGs were performed immediately prior to each blood draw, for a total of 13 recordings in the placebo period and 13 recordings in the treatment period. ECGs were obtained with the subject resting supine for approximately 15 min prior to acquisition using a MAC 5000 ECG machine (GE Medical Systems, Milwaukee, WI, USA). We acquired 12 lead ECGs at a paper speed of 50 mm/s and amplitude of 20 mm/mV. The electrocardiograms were printed in a format that displayed rhythm strips from all 12 leads simultaneously in order to facilitate identification of the earliest Q wave and latest T wave.
Analysis of Blood Samples Genotype determination
Blood samples for genotype determination were collected in Vacutainer s tubes (Becton-Dickinson, Franklin Lakes, NJ, USA) containing sodium heparin. The blood was then transferred into a cryogenic vial (Corning, Cambridge, MA, USA) for storage at À201C. Genomic DNA was extracted from the leukocyte portion of whole blood using a QIAamp DNA blood Midi Kit s (Qiagen, Valencia, CA, USA). Screening for CYP2D6 alleles *1, *3, *4, *6, *8, *10, and *17 was performed as previously described 25 using amplification of a 4.7 kilo base pair (kbp) fragment containing all nine exons, followed by nested polymerase chain reactions (PCR) for each genetic variant tested.
The final amplification mixture for the 4.7 kbp long template PCR product (LT-PCR) was 50 ml. It was prepared as two separate mixtures of 25 ml each. The first of these was a mixture containing 17.5 ml of water, 1.7 ml of dNTP's, 0.3 ml each of forward and reverse primers and 5 ml of genomic DNA (B500 ng). The second 25 ml mixture contained 19.25 ml of water, 5 ml of buffer (NE Biolabs #3), and DNA Taq Polymerase 0.75 ml. Both mixtures were prepared on ice and mixed by gentle vortexing just prior to thermocycling. The details of the thermocycling conditions of the LT-PCR product are shown in Table 4 . The LT-PCR product was diluted with 200 ml of Tris-EDTA buffer and stored at À201C for later use in nested/allele specific PCRs.
The nested or allele specific PCRs for *3, *4, *6, *8, *10, *17 were all prepared at a volume of approximately 25 ml. Each mixture contained 22.5 ml of Platinum Supermix, 1.5 ml of distilled water, 1 ml of LT-PCR product, and 0.25 ml each of forward and reverse primers. The details of the thermocycling conditions for alleles *3, *4, *6, *8, *10, *17 are shown in Table 5 . All forward and reverse primers for the LT-PCR product and allele-specific PCR products as well as allele specific restriction enzymes are listed in Table 6 .
Pharmacokinetics
Approximately 7 ml of whole blood was collected into a red top Vacutainer s tubes and immediately separated by centrifugation at 4000 Â g for 10 min followed by transfer into a cryogenic tube and refrigeration at À201C. Plasma concentrations of haloperidol and reduced haloperidol were Table 6 Allele specific primers and restriction enzymes Primers (forward(F) and reverse(R)) Restriction enzyme
This table provides a list of both the forward and reverse primers used in genotyping for various alleles of CYP2D6 along with the associated allele-specific restriction enzymes.
Haloperidol pharmacokinetics and pharmacodynamics M Desai et al analyzed using liquid chromatography/mass spectrometry (LC/MS) (Finnigan AQA, San Jose, CA, USA). A 0.5 ml sample of plasma was mixed with 20 ml of internal standard [1 mg/ml of chlorinated haloperidol (Sigma RBI, St Louis, MO, USA)] and 250 ml of 1 M NaOH/glycine buffer, pH ¼ 11.3, in a 13 Â 100 mm disposable culture tube (Fischer Scientific, Pittsburgh, PA, USA). To the mixture, 4 ml of cyclohexane/methylene chloride (7 : 3, v : v) was added. All samples were mixed vigorously for 15 s using a platform mixer. The samples were then centrifuged in a Sorvall RT 6000D s centrifuge (Sorvall, Wilmington, DE, USA) at 2800 rpm for 5 min. The organic phase was transferred to a clean disposable culture tube and evaporated to dryness using a Savant SpeedVac Concentrator s (Thermo-Savant, Farmingdale, NY, USA). The residue was reconstituted with 120 ml of mobile phase and the contents were transferred into a polypropylene tube inside an autosampler vial. A volume of 40 ml was injected into the LC-MS. A Luna 3 m CN 100 Â 2.00 mm column (Phenomenex, Torrance, CA, USA) was used. Two mobile phases were used: 10 mM ammonium formate, pH ¼ 5.0 (80%), acetonitrile (20%) and 10 mM ammonium formate, pH ¼ 5.0 (20%), acetonitrile (80%). The flow rate was 0.25 ml/min (30% of the former mobile phase and 70% of the latter mobile phase). Mean retention times were 8.6 min (reduced haloperidol), 10.4 min (haloperidol), 11.7 min (chlorinated haloperidol). Linear standard curves were obtained over the range of 0.5-20 ng/ml for both haloperidol and reduced haloperidol. The limit of quantification for haloperidol and reduced haloperidol was 0.5 ng/ml. The precision for haloperidol and reduced haloperidol at 1.4, 8.0, and 16.0 ng/ml was less than 12.4 and 13.1%, respectively. The accuracy for haloperidol ranged from 86 to 108% at 1.4 ng/ml, 94 to 112% at 8.0 ng/ml and 84 to 108% at 16.0 ng/ml. The accuracy for reduced haloperidol ranged from 82 to 106% at 1.4 ng/ml, 100 to 116% at 8.0 ng/ml, and 98 to 124% at 16.0 ng/ml.
QT Interval Analysis
A trained physician blinded to time, treatment, and patient identity, used a previously described and validated computer-operator interactive method to measure QT intervals 26 from number coded ECGs acquired during the study. The ECG tracings were placed on a digitizing pad (Summagraphics s , Hacienda Heights, CA, USA) that was connected to a personal computer. A cross-hair pointing device was used to mark the beginning and end of the QT interval as well as the preceding RR interval among three consecutive beats in which the RR interval was relatively constant. The average of the three consecutive RR and QT intervals was used. The QT interval was corrected for heart rate variability using an approach described by Malik. 27 This method involved plotting the RR interval vs QT interval relation derived from each subject's placebo period data and fitting these data to a linear mixed model of the form log QT ij ¼ B i þ a i log RR ij þ e ij where e B i was the subject specific QT in seconds when the RR interval was 1 s, a i was the slope of the log transformed RR vs QT relation, and e ij was an error term. The subscripts i and j referred to an individual subject i at a certain time point j. A mathematical manipulation of the linear model described, yielded a correction of the form: QT c ij ¼ QT ij = ðRR ij Þ a i . The correction for each individual derived from the placebo period data was applied to the treatment period data.
Statistical and Power Analysis
Given a sample size of 16 subjects in a crossover trial, there was 80% power to detect a difference between the haloperidol-and placebo-treated groups of 13 ms or greater at an a level of 5%. This was based on the assumption that the intersubject standard deviation of the absolute QT c (Bazett's correction) was approximately 18 ms. 28 For the purpose of analysis, we categorized only the *4 homozygotes as PMs and all other genotypes as EMs. A twotailed, nonparametric (Mann-Whitney U-test) was used to compare pharmacokinetic parameters with respect to sex, CYP2D6 genotype, and haloperidol-induced side effects.
Slope comparisons of the QT c vs RR linear regression lines for the three heart rate correction formulae (Bazett, Fredericia, and subject specific) were performed using a nonparametric test (Mann-Whitney U).
The mean, time averaged QT c 's between males and females during the placebo period were assessed using an unpaired, two-tailed, unequal variance t-test. A paired t-test was used to compare the mean QT c on treatment at a given time point vs the mean QT c on placebo at the corresponding time point. Since 13 t-test comparisons were made inclusive of the baseline and 96-h time points, a Bonferonni correction for multiple comparisons was performed. Changes in heart rate were analyzed in a similar way.
